Cited by 618Clostridium difficile and Clostridium perfringens researchGut microbiota and healthGastrointestinal motility and disorders

Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection

Open access
Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., Iqbal, T. H.·2017·Alimentary Pharmacology & Therapeutics

Abstract

BACKGROUND: Clostridium difficile infection (CDI) is the commonest nosocomial cause of diarrhoea. Faecal microbiota transplantation (FMT) is an approved treatment for recurrent or refractory CDI but there is uncertainty about its use. AIM: To evaluate the efficacy of FMT in treating recurrent and refractory CDI and investigate outcomes from modes of delivery and preparation. METHODS: A systematic review and meta-analysis was performed. MEDLINE, EMBASE, CINAHL, Cochrane Library, trial registers and conference proceedings were searched. Studies on FMT in recurrent and refractory CDI were included. The primary outcome was clinical resolution with subgroup analyses of modes of delivery and preparation. Random effects meta-analyses were used to combine data. RESULTS: Thirty seven studies were included; seven randomised controlled trials and 30 case series. FMT was more effective than vancomycin (RR: 0.23 95%CI 0.07-0.80) in resolving recurrent and refractory CDI. Clinical resolution across all studies was 92% (95%CI 89%-94%). A significant difference was observed between lower GI and upper GI delivery of FMT 95% (95%CI 92%-97%) vs 88% (95%CI 82%-94%) respectively (P=.02). There was no difference between fresh and frozen FMT 92% (95%CI 89%-95%) vs 93% (95%CI 87%-97%) respectively (P=.84). Administering consecutive courses of FMT following failure of first FMT resulted in an incremental effect. Donor screening was consistent but variability existed in recipient preparation and volume of FMT. Serious adverse events were uncommon. CONCLUSION: Faecal microbiota transplantation is an effective treatment for recurrent and refractory Clostridium difficile infection, independent of preparation and route of delivery.

Integrity signals

Registry

Crossref · 10.1111/apt.14201

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Cites

Flagged first, then by citations

1 of the 70 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H.
Affiliations
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University Hospital Coventry (GB)
  • University of Birmingham (GB)
Corresponding author
Iqbal, T. H.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2017-07-14
Volume
46
Issue
5
Pages
479-493
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2735259022
Cited by
617
References
70
Citations by year
2026: 41 · 2025: 53 · 2024: 68 · 2023: 75 · 2022: 87 · 2021: 81 · 2020: 95 · 2019: 73 · 2018: 38 · 2017: 6
FWCI
8.95
Type
journal article
Language
en
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
National Institute for Health and Care Research (13/179/01, EME/13/179/01)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
fecal microbiota transplantation, Clostridium difficile infection, recurrent Clostridium difficile infection, vancomycin, mode of delivery, donor screening, recipient preparation, nosocomial diarrhea, adverse events
MeSH terms
Fecal Microbiota Transplantation, Clostridium Infections, Cross Infection, Diarrhea, Humans, Vancomycin, Randomized Controlled Trials as Topic, Clostridioides difficile, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review